Regeneron
Regeneron announces presentations of new data on Eylea HD for retinal disease
February 18, 2026Research and Development Eylea HD, Opthalmology, Regeneron
Regeneron has presented data for Eylea HD (aflibercept) 8mg injection for retinal disease. The data was presented as part of …
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
September 26, 2025Research and Development Dupixent, Regeneron, Sanofi, urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
Dupixent improves symptoms in patients with skin of colour, study shows
June 11, 2025Advocacy Development, Medical Education, Research and Development Dermatology, Dupixent, Regeneron, Sanofi, atopic dermatitis, dermatology, underserved populations
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, …
Dupixent approved as first biologic medicine in Japan for COPD patients
April 2, 2025Research and Development COPD, Chronic Diseases, Regeneron, Sanofi, biotech, respiratory disease
The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment …
Regeneron and Mammoth Biosciences announce CRISPR collaboration
April 26, 2024Research and Development Pharmacy, Regeneron, crispr, gene editing
Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration for the research, development and commercialisation of in vivo CRISPR-based gene …
FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review
February 22, 2024Medical Communications FDA, Oncology, Regeneron, bla, priority review
Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for …
Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment
February 5, 2024Medical Communications EMA, Oncology, Regeneron, linvoseltamab, multiple myeloma
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorisation Application (MAA) for …
Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio
January 31, 2024Business Services 2seventy bio, Pharmacy, Regeneron, Regeneron Cell Medicines, acquisition
Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio to acquire the …
Regeneron shares data for multiple myeloma treatment
December 8, 2023Medical Communications Cancer, Oncology, Regeneron, clinical trial
Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …
Regeneron plans to share advancements from blood cancer pipeline
November 6, 2023Medical Communications ASH annual meeting, Haematology, Regeneron, blood cancer, haematology
Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its haematology pipeline at the American …
Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review
September 26, 2023Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi
Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has accepted their supplemental Biologics License …
Regeneron shares two-year PULSAR trial results for wAMD
August 11, 2023Medical Communications Opthalmology, PULSAR trial, Regeneron, wAMD
Regeneron Pharmaceuticals have announced positive, two-year, topline results from its PULSAR trial assessing aflibercept 8mg for the treatment of patients …
Regeneron’s drug cocktail shown to prevent symptomatic COVID-19
April 13, 2021Manufacturing and Production COVID-19, REGEN-COV, Regeneron, covid-19 treatment, pharma, pharma news
Regeneron’s REGEN-COV treatment cocktail for COVID-19, a combination between casirivimab and imdevimab, has shown a significant reduction in progression to …
Phase III trial of Libtayo stopped early after positive overall survival results
March 15, 2021Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi
A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …
FDA approves Regeneron’s Evkeeza for HoFH
February 12, 2021Medical Communications FDA, Regeneron
The FDA has approved Regeneron’s Evkeeza (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat …
